Welcome to our dedicated page for Sophia Genetics Sa SEC filings (Ticker: SOPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SOPHiA GENETICS SA filings document the disclosures of a foreign private issuer that reports through Form 6-K and related registration statements. The company’s filings include unaudited interim condensed consolidated financial statements, management discussion and analysis, press releases on operating results, and Swiss annual report materials tied to its AI-driven precision medicine software business.
Other filings cover annual general meeting notices, proxy materials, shareholder voting documents, incorporation by reference into Form F-3 and Form S-8 registration statements, and capital-structure matters such as credit-agreement amendments, term loan commitments, warrants, and ordinary-share purchase rights.
SOPHiA GENETICS SA Chief Financial Officer George Cardoza reported an open-market sale of 774 Ordinary Shares on March 19, 2026 at a weighted average price of $4.7862 per share. The footnotes state this sale was made solely to satisfy tax withholding obligations from restricted stock units that vested on March 18, 2026, under a pre-established Rule 10b5-1 trading plan and was not a discretionary trade. After the transaction, Cardoza directly holds 184,858 Ordinary Shares, indicating this was a small, routine tax-related sale relative to his remaining position.
ZHENYU XU reported 10b5-1 sales of Common Stock under multiple transactions. The filing lists periodic 10b5-1 dispositions on 01/05/2026, 01/06/2026, 01/13/2026, 01/20/2026, 02/13/2026, 02/19/2026, and 03/13/2026, with reported share amounts of 2006, 3000, 4000, 608, 4000, 608, and 4000 respectively and per-trade proceeds shown in the filing.
The filing also lists 608 Restricted Stock Units to be sold by the issuer on 03/18/2026. Transactions were processed through Morgan Stanley Smith Barney LLC.
Morgan Stanley Smith Barney LLC submitted a Form 144 listing 684 Restricted Stock Units to be sold on 03/18/2026 for SOPH. The filing also records prior 10b5-1 dispositions by Daan Guido Maria van Well on 01/05/2026 (2,051 shares), 01/06/2026 (2,056 shares), 01/20/2026 (684 shares) and 02/19/2026 (684 shares).
SOPH: notice of proposed resale of Common Stock tied to Restricted Stock Units. The filing lists 1,183 Restricted Stock Units scheduled on 03/18/2026 for sale. The excerpt also discloses recent Rule 10b5-1 dispositions: examples include 760 shares sold on 02/19/2026 for $3,665.94 and 4,200 shares sold on 01/06/2026 for $20,013.84.
SOPH: A Form 144 notice lists a proposed sale of 774 Restricted Stock Units of Common Stock dated 03/18/2026 by Morgan Stanley Smith Barney LLC Executive Financial Services. The filing also records prior 10b5-1 sales of 856 shares on 12/22/2025 attributed to George Cardoza.
Morgan Stanley Smith Barney LLC filed a Rule 144 notice relating to 608 Restricted Stock Units dated 03/18/2026 to be sold. The entry lists the securities as Common and identifies the issuer role as Issuer.
The filing also shows recent 10b5-1 sales by Philippe Menu, including transactions of 5,000 shares on 03/12/2026 for $22,592.50 and 608 shares on 02/19/2026 for $2,932.38.
Manuela Valente reported sales of Common Stock under Rule 144 via pre-arranged 10b5-1 transactions. The filing lists multiple dispositions: 01/05/2026 2,085 shares, 01/06/2026 636 shares, 01/20/2026 380 shares, and 02/19/2026 380 shares. The trades show an executing broker Morgan Stanley Smith Barney LLC and reference Restricted Stock Units as the security type.
JURGI CAMBLONG reported multiple 10b5-1 sales of Common stock executed through Morgan Stanley Smith Barney LLC as broker. The excerpt lists individual sales from 12/29/2025 through 03/16/2026 with per-trade share counts and proceeds.
Examples shown include sales of 95,488 shares on 01/09/2026 and 37,299 shares on 01/22/2026, executed under a 10b5-1 plan. The filing lists Restricted Stock Units and trade dates; cash-flow treatment is not stated in the provided excerpt.
SOPHiA GENETICS SA director Tomer Berkovitz filed an initial Form 3, which is a baseline report of insider status and equity interests. This filing does not list any insider transactions or derivative positions in the provided data, and serves as an initial ownership disclosure for this director.
SOPHiA GENETICS SA director Kathy L. Hibbs filed an initial ownership report showing holdings in ordinary shares and share options. She reports 97,276 ordinary shares, including 33,784 shares underlying restricted share units that vest in full at the company’s next annual shareholder meeting, subject to continued service. She also holds fully vested and exercisable options over 140,000 ordinary shares at an exercise price of 5.9800 per share expiring on March 26, 2031, and options over 49,751 ordinary shares at 3.0400 per share expiring on June 18, 2035.